Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohortsThomas K. Karikari, Kaj Blennow|The Lancet Neurology|2020Cited by 1.3k
Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease ContinuumAndréa Lessa Benedet, Natàlia Vilor‐Tejedor, Alyssa Stevensson et al.|JAMA Neurology|2021Cited by 627
A multicentre validation study of the diagnostic value of plasma neurofilament lightNicholas J. Ashton, Oskar Hansson, Shorena Janelidze et al.|Nature Communications|2021Cited by 554
Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detectedMarc Suárez‐Calvet, Natàlia Vilor‐Tejedor, Thomas K. Karikari et al.|EMBO Molecular Medicine|2020Cited by 411
The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's diseaseJoel Simrén, Nicholas J. Ashton, Antoine Leuzy et al.|Alzheimer s & Dementia|2021Cited by 354